Photo of Paul Baumbach
D Delaware House · District 23

Rep. Paul Baumbach

Contact Email
Compare
Total votes
2,122
all sessions
Attendance
99%
14 missed
Higher than 95% of chamber peers
With party
99%
of cast votes
Near the chamber average
Bipartisan score
0%
crosses aisle rarely
Near the chamber average
Sponsored
1,430
bills & resolutions
Higher than 88% of chamber peers
Committees
0
assignments
1,430 bills and resolutions

Sponsored bills

Total
1,430
Primary
633
Co-sponsor
797
This page
1,430
matching current filters
Co-sponsor SB 81
Passed · Delaware Senate · Co-sponsor
AN ACT TO AMEND TITLE 24 OF THE DELAWARE CODE RELATING TO LICENSE TO PRACTICE DENTISTRY.

This Act permits an individual to practice dentistry for the Division of Public Health (Division) under a provisional license. Delaware law provides several routes for entering practice on an interim basis until full licensure can be obtained, however, none of these routes specifically permit hiring by the Division with the intent to practice in a state-supported dental clinic. This Act will assist the Division in recruiting dentists to serve those in need. This Act also makes technical corrections to conform existing law to the standards of the Delaware Legislative Drafting Manual.

Passed Jun 12, 2019 1 co-sponsor
Co-sponsor HB 181
In committee · Delaware House · Co-sponsor
AN ACT TO AMEND TITLE 13 OF THE DELAWARE CODE REGARDING ADOPTION OF THE MODEL RELOCATION ACT.

This bill adopts the majority of the Model Relocation Act proposed by the American Academy of Matrimonial Lawyers relating to the relocation of the principal residence of a child. When deciding a custody case in which an individual is seeking to relocate a child outside of the State, many judges in Family Court refer to the Model Relocation Act when reaching their decisions. However, the Model Relocation Act is only persuasive in these decisions and is not required to be considered by the Court. Therefore, this bill codifies the Model Relocation Act to require its consideration in a Court’s analysis during these types of proceedings and provides a more structure guideline for the Court when deciding such decisions.

In committee Jun 12, 2019 1 co-sponsor
Co-sponsor SB 34
Signed into law · Delaware Senate · Co-sponsor
AN ACT TO AMEND TITLE 16 OF THE DELAWARE CODE CREATING A PRESCRIPTION OPIOID IMPACT FUND.

This Act creates a Prescription Opioid Impact Fund (“Fund”) through a prescription opioid impact fee (“Fee”) that is paid by pharmaceutical manufacturer. The anticipated revenue from the Fee is $2.8 million in 2020, $2.7 million in 2021, and $2.5 million in 2022.: 1. The fee is based on the total of the Morphine Milligram Equivalent (“MME”) in each manufacturer’s products dispensed in Delaware, based upon data already reported to the Prescription Monitoring Program (“PMP”). The PMP data contains the mandatory reports by pharmacists of every prescription opioid dispensed in the State. The PMP data does not include prescription opioids administered in hospitals, provided directly to patients by hospice, or dispensed by veterinarians. 2. The fee is assessed on manufacturers who exceed a threshold of 100,000 MMEs dispensed each quarter. 3. The Fee is calculated at a rate of either 1 penny per MME for a name brand prescription opioid dispensed and reported in the PMP or ¼ of a penny per MME for a prescription opioid that is a generic. The Act also provides that Secretary of the Department of Health and Social Services, after receiving recommendations from the Behavioral Health Consortium, the Addiction Action Committee, and the Overdose System of Care Committee, will award grants and contracts from the money in the Fund for the following activities: 1. Opioid addiction prevention. 2. Opioid addiction services, including the following: 3. Inpatient and outpatient treatment programs and facilities, including short-term and long-term residential treatment programs and sober living facilities. 4. Treating substance use disorder for the under-insured and uninsured. 5. Emergency assistance relating to prescription opioids, including purchasing Naloxone. 6. Administrative costs of implementing the Fee and Fund, up to 15% of the amount in the Fund. Finally, this Act expires in 5 years, unless terminated sooner or extended by the General Assembly, so that the Fee is only continued if it is effective and is not creating negative unintended consequences.

Signed into law Jun 12, 2019 1 co-sponsor
Primary HB 176
In committee · Delaware House · Lead sponsor
AN ACT TO AMEND TITLES 16 AND 18 OF THE DELAWARE CODE RELATING TO THE DELAWARE HEALTH INSURANCE INDIVIDUAL MARKET STABILIZATION REINSURANCE PROGRAM.

This Act creates the Delaware Health Insurance Individual Market Stabilization Reinsurance Program & Fund (the “Program”). The Program will be administered by the Delaware Health Care Commission in order to provide reinsurance to health insurance carriers that offer individual health benefit plans in Delaware. The Program will be funded with pass-through funds received from the federal government under the Affordable Care Act, funds provided by the Federal Government for reinsurance, and through a 2.75% annual assessment based on insurance carrier’s premium tax liability.

In committee Jun 11, 2019 0 co-sponsors
Primary HB 204
In committee · Delaware House · Lead sponsor
AN ACT TO AMEND TITLE 11 OF THE DELAWARE CODE RELATING TO CRIMINAL IMPERSONATION.

In a case of first impression, the Superior Court ruled, contrary to "common knowledge" of Delaware Criminal laws, that criminal impersonation requires proof that a real person (a human being who has been born and is alive) has been impersonated; in other words, one cannot impersonate a fictitious person. Evans v. State, Del. Super., April 30, 2019. This Act provides that criminal impersonation occurs when one impersonates a real or fictitious person.

In committee Jun 11, 2019 0 co-sponsors
Showing 1,091 to 1,100 of 1,430 bills